Alk7 binding proteins and uses thereof
AssigneesAcceleron Pharma Inc., Adimab, LLC
InventorsRavindra Kumar, Roselyne Castonguay, Dianne Sako, Jonathan Belk, Nathan J. Sharkey
Life of this patent
Estimating the term…
Loading patent…
AssigneesAcceleron Pharma Inc., Adimab, LLC
InventorsRavindra Kumar, Roselyne Castonguay, Dianne Sako, Jonathan Belk, Nathan J. Sharkey
Estimating the term…
This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
An Activin Receptor-Like Kinase 7 (ALK7)-binding protein that specifically binds at least one primary epitope of an ALK7 protein, wherein the at least one primary epitope is essentially the same as an epitope selected from SEQ ID NOs:310, 313, and 317.
(canceled)
(canceled)
(canceled)
(canceled)
An ALK7-binding protein that binds an overlapping epitope on ALK7, wherein the overlapping epitope shares at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or more identical amino acid residues with the epitopes set forth in SEQ ID NOs:310-319.
15-33. (canceled)
(canceled)
(canceled)
40-41. (canceled)
(canceled)
46-50. (canceled)
52-53. (canceled)
Dependencies are inferred from the claim text.